Medivir: Interim results (SVR4) from a phase II all-oral combination study of Simeprevir and Samatasvir (IDX719) for the

  Medivir: Interim results (SVR4) from a phase II all-oral combination study
  of Simeprevir and Samatasvir (IDX719) for the treatment of hepatitis C

Business Wire

STOCKHOLM, Sweden -- January 13, 2014

Regulatory News:

Sweden—Medivir AB (STO:MVIR-B), announces that Idenix Pharmaceuticals, Inc.
today released interim data from the ongoing phase II HELIX-1 clinical trial
evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen
of samatasvir (IDX719), Idenix’s once-daily pan-genotypic NS5A inhibitor, and
simeprevir , a once-daily protease inhibitor jointly developed by Janssen R&D
Ireland and Medivir AB, and ribavirin.

The combination regimen of the study was well-tolerated. In the
treatment-naïve, non-cirrhotic, genotype 1b or 4 HCV-infected patients
receiving 50 mg of samatasvir and 150 mg of simeprevir plus ribavirin for 12
weeks, 85 percent (n=17/20) of the patients achieved SVR4 (undetectable HCV
RNA four weeks after end of treatment). The 50 mg dose of samatasvir is the
selected dose in the ongoing 3-DAA HELIX-2 clinical trial. The HELIX-1 study
results are expected to be presented at a scientific meeting in 2014.

HELIX-1 study design The HELIX-1 trial is the first study in HCV-infected
patients to commence under a non-exclusive collaboration agreement between
Idenix and Janssen which was established in January 2013. The HELIX-1 trial is
a phase II 12-week, randomized, parallel group study evaluating the antiviral
activity, safety and tolerability of samatasvir and simeprevir in
treatment-naïve, non-cirrhotic, genotype 1b or 4 HCV-infected patients.

Patients in part A of the study (n=63) were enrolled in one of three treatment
groups receiving 50, 100, or 150 mg samatasvir once-daily for 12 weeks in
combination with 150 mg of simeprevir plus a weight-based dose of ribavirin.
In part B of the ongoing HELIX-1 study, exploratory cohorts of patients have
been added to evaluate the safety and antiviral activity of a 25 mg dose of
samatasvir in genotype 1b-infected patients and of a 100 mg dose of samatasvir
in genotype 6-infected patients.

A second phase II trial (HELIX-2) was initiated in December 2013 evaluating
samatasvir, simeprevir and TMC647055, a once-daily non-nucleoside polymerase
inhibitor plus a low-dose ritonavir being developed by Janssen, with and
without ribarivin in genotype 1-infected patients who are either
treatment-naïve or have previously relapsed after treatment with pegylated
interferon and ribavirin.

For additional information about the HELIX-1 study, please visit

Medivir is required under the Securities Markets Act to make the information
in this press release public. The information was submitted for publication at
13.15 p.m. CET on 13 January 2014.

About Simeprevir Simeprevir is an NS3/4A protease inhibitor jointly developed
by Medivir and Janssen R&D Ireland for the treatment of chronic hepatitis C
infection in combination with other antivirals in HCV genotype 1 and 4
infected subjects with compensated liver disease, including cirrhosis.

Simeprevir was approved for the treatment of genotype 1 hepatitis C in
September 2013 in Japan (trade name Sovriad™) and in the USA (trade name
Olysio™) and Canada (trade name Galexos™) in November. A Marketing
Authorisation Application was submitted to the European Medicines Agency (EMA)
in April 2013 by Janssen-Cilag International NV seeking approval of simeprevir
for the treatment of genotype 1 and genotype 4 chronic hepatitis C. To date,
more than 3,700 patients have been treated with simeprevir in clinical trials.

About Samatasvir (IDX719)

Samatasvir is an NS5A inhibitor with low picomolar, pan-genotypic antiviral
activity in vitro. To date, samatasvir has been safe and well-tolerated after
single and multiple doses of up to 150 mg in healthy volunteers up to 14 days
duration, and in HCV-infected patients up to 12 weeks duration. There have
been no treatment-emergent serious adverse events reported in the program.
Samatasvir has demonstrated potent pan-genotypic antiviral activity in
HCV-infected patients with mean maximal viral load reductions up to
approximately 4.0 log10 IU/mL across HCV genotypes 1-4 in a proof-of-concept,
three-day monotherapy study.

About Medivir

Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is
simeprevir, a novel protease inhibitor for the treatment of hepatitis C that
is being developed in collaboration with Janssen R&D Ireland. The company is
also working with research and development in other areas, such as bone
disorders and neuropathic pain. Medivir has also a broad product portfolio
with prescription pharmaceuticals in the Nordics.

For more information about Medivir AB, please visit the Company’s website:

This information was brought to you by Cision


For more information please contact:
Rein Piir, EVP Corporate Affairs & IR,
mobile: +46 708 537292
Press spacebar to pause and continue. Press esc to stop.